What dual‑marker (combined first‑trimester) screening test should be performed for a pregnant patient at 11–13 weeks + 6 days gestation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dual Marker Test for First-Trimester Screening

The dual-marker test at 11-13 weeks + 6 days gestation should measure maternal serum PAPP-A (pregnancy-associated plasma protein-A) and free β-hCG (free beta-subunit of human chorionic gonadotropin), combined with ultrasound measurement of fetal nuchal translucency (NT) and maternal age to calculate risk for trisomy 21,18, and 13. 1, 2

Core Components of the Test

The combined first-trimester screening consists of:

  • Biochemical markers:

    • PAPP-A (pregnancy-associated plasma protein-A)
    • Free β-hCG (preferred over total/intact hCG at this gestational age)
  • Ultrasound measurement:

    • Nuchal translucency (NT) thickness
  • Clinical factor:

    • Maternal age

Why Free β-hCG Over Total hCG

Between 11 and 13 gestational weeks, free β-hCG is univariately a more discriminatory marker than total hCG. 2 When combined with maternal age, NT, and PAPP-A:

  • Free β-hCG performs 2-3% better than total hCG at 11 weeks
  • At 13 weeks, total hCG may perform only 1-2% better than free β-hCG
  • The overall superior performance of free β-hCG makes it the preferred marker 2

Expected Performance

At a 5% false-positive rate, the detection rates for trisomy 21 are:

  • 11 weeks: 86% detection rate
  • 12 weeks: 84% detection rate
  • 13 weeks: 82% detection rate 2

More recent data from large prospective studies shows even better performance when properly implemented 3:

  • At 3% false-positive rate: 85-92% detection (depending on gestational week)
  • At 5% false-positive rate: 90-94% detection

Pattern Recognition for Trisomies

Trisomy 21 (Down syndrome):

  • Increased free β-hCG
  • Decreased PAPP-A
  • Increased NT
  • Increased maternal age 4, 5

Trisomies 18 and 13:

  • Decreased free β-hCG (opposite of trisomy 21)
  • Decreased PAPP-A
  • Increased NT
  • Increased maternal age 5

Critical Implementation Details

Timing optimization: While the test window is 11-13+6 weeks, biochemical marker performance varies by gestational age. PAPP-A shows maximum discrimination at 9-10 weeks, while free β-hCG discrimination increases linearly through the first trimester 6. However, for practical single-visit combined screening at 11-13+6 weeks, the test performs well when both markers are measured simultaneously with NT 1, 2.

Marker adjustment: The laboratory must adjust MoM (multiples of the median) values for:

  • Maternal weight
  • Ethnicity/racial origin
  • Smoking status
  • Method of conception
  • Parity 3

Common Pitfalls to Avoid

  • Do not use total/intact hCG instead of free β-hCG at 11-12 weeks, as this reduces detection rates by 2-3% 2
  • Ensure NT measurement quality control - laboratories should monitor sonographer performance and have protocols to address discrepancies 1
  • Do not screen before 11 weeks - the combined test is validated for 11-13+6 weeks specifically 1, 2

Follow-Up for Screen-Positive Results

Screen-positive patients should be offered:

  • Genetic counseling
  • Non-invasive prenatal testing (NIPT) as a secondary screen
  • Diagnostic testing (CVS or amniocentesis) 4

Recent data shows that among high-risk first-trimester screens, NIPT can further refine risk before proceeding to invasive diagnostic testing 4.

Related Questions

What does a low PAPP‑A (pregnancy‑associated plasma protein‑A) multiple‑of‑the‑median in a dual‑marker first‑trimester screen indicate, and what are the recommended next steps for management?
What is the recommended protocol for Enhanced First Trimester Screening (EFTS) using the First Trimester Quadruple Test (FTQT)?
What prenatal tests and screenings should be ordered in the first trimester of pregnancy?
In a pregnant woman with low first‑trimester pregnancy‑associated plasma protein‑A (PAPP‑A), what is the risk of developing pre‑eclampsia and what prophylactic management is recommended?
For a 38‑year‑old woman with a prior miscarriage and normal results on non‑invasive prenatal testing (NIPT), first‑trimester ultrasound with nuchal translucency, and combined serum hCG and PAPP‑A screening, does the combined screening provide high sensitivity for Down syndrome such that invasive testing (e.g., chorionic villus sampling) is unnecessary?
What is the appropriate dosing and monitoring of patiromer (Veltassa) in a dialysis patient with hyperkalemia?
What is the appropriate infusion rate of 25% dextrose solution for a burn patient versus a non‑burn patient with acute hypoglycemia, and does rapid or free‑flow administration cause harm?
How should hyperkalemia be managed in a dialysis patient with a serum potassium of 5.9 mEq/L?
Can I prescribe Lokelma (sodium‑zirconium cyclosilicate) 10 g on non‑dialysis days for a dialysis patient whose most recent pre‑dialysis potassium is 5.9 mEq/L?
Given a free T4 level of 0.90 ng/dL (within normal range) and a TSH level of 3.7 mIU/L (high‑normal), how often should these be monitored and is a separate T3 measurement indicated?
What is the appropriate antibiotic regimen for a patient with sinusitis who has a penicillin allergy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.